BioLife Solutions, Inc. (NASDAQ:BLFS) Receives Consensus Recommendation of "Buy" from Analysts

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) have been assigned an average rating of "Buy" from the seven analysts that are presently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $29.00.

BLFS has been the topic of several recent analyst reports. HC Wainwright cut their price objective on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, November 18th. Benchmark reaffirmed a "buy" rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. Craig Hallum raised their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. TD Cowen boosted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Finally, KeyCorp increased their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a report on Friday, December 13th.

BioLife Solutions Trading Up 0.5 %

BLFS stock traded up $0.12 during midday trading on Tuesday, hitting $26.50. 106,613 shares of the company's stock were exchanged, compared to its average volume of 386,029. BioLife Solutions has a one year low of $14.50 and a one year high of $28.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The company has a market cap of $1.23 billion, a PE ratio of -25.00 and a beta of 1.91. The stock's fifty day moving average price is $25.08 and its 200-day moving average price is $23.84.

Insiders Place Their Bets

In other BioLife Solutions news, EVP Aby J. Mathew sold 25,000 shares of the business's stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $21.17, for a total transaction of $529,250.00. Following the transaction, the executive vice president now owns 302,046 shares of the company's stock, valued at $6,394,313.82. The trade was a 7.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 64,259 shares of company stock valued at $1,424,708 in the last three months. 2.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BioLife Solutions

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Mark Sheptoff Financial Planning LLC bought a new stake in BioLife Solutions during the third quarter worth $28,000. Isthmus Partners LLC raised its holdings in shares of BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 42,265 shares during the period. Quest Partners LLC acquired a new stake in BioLife Solutions in the 3rd quarter valued at about $57,000. GAMMA Investing LLC grew its holdings in BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider's stock worth $83,000 after purchasing an additional 748 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new position in BioLife Solutions during the second quarter worth approximately $122,000. 93.24% of the stock is owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.